Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The high-mannose patch on HIV Env is a preferred target for broadly neutralizing antibodies (bnAbs), but to date, no vaccination regimen has elicited bnAbs against this region. Here, we present the development of a bnAb lineage targeting the high-mannose patch in an HIV-1 subtype-C-infected donor from sub-Saharan Africa. The Abs first acquired autologous neutralization, then gradually matured to achieve breadth. One Ab neutralized >47% of HIV-1 strains with only ∼11% somatic hypermutation and no insertions or deletions. By sequencing autologous env, we determined key residues that triggered the lineage and participated in Ab-Env coevolution. Next-generation sequencing of the Ab repertoire showed an early expansive diversification of the lineage followed by independent maturation of individual limbs, several of them developing notable breadth and potency. Overall, the findings are encouraging from a vaccine standpoint and suggest immunization strategies mimicking the evolution of the entire high-mannose patch and promoting maturation of multiple diverse Ab pathways.

Original publication

DOI

10.1016/j.immuni.2016.04.016

Type

Journal article

Journal

Immunity

Volume

44

Pages

1215 - 1226

Keywords

AIDS Vaccines, Africa South of the Sahara, Antibodies, Neutralizing, Antibody Diversity, B-Lymphocytes, Biological Evolution, Cell Differentiation, Complementarity Determining Regions, HIV Antibodies, HIV Infections, HIV-1, High-Throughput Nucleotide Sequencing, Humans, Immunodominant Epitopes, Lymphocyte Activation, Mannose, env Gene Products, Human Immunodeficiency Virus